Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb
News Feb 08, 2008
Cell Signaling Technology, Inc. (CST) announced the continuation of a research agreement with Bristol-Myers Squibb Company under which CST will employ its patented PhosphoScan® technology in the cell and tumor phospho-profiling of a Bristol-Myers Squibb small-molecule kinase inhibitor.
The PhosphoScan® profiling research project builds on a successful evaluation project between the two companies, which was completed in March 2007, and will involve in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.
PhosphoScan® proteomics is a patented strategy for broad profiling of phosphorylation in cells and tissues. The PhosphoSignatures™ generated with the Bristol-Myers Squibb compound will be analyzed and understood within the context of CST’s PhosphoSignature™ database covering hundreds of cancer cell lines and human tumors.
PhosphoScan® profiling involves immunoaffinity purification and tandem mass spectroscopy and its effectiveness in kinase target and biomarker discover in cancer was illustrated most recently in the journal Cell.
“Our PhosphoScan® profiling research with Bristol-Myers Squibb has been very successful and we are glad to have the opportunity to extend that research in analysis of Bristol-Myers Squibb’s kinase inhibitors in tumor models,” said Christopher Bunker, CST’s Director of Business Development.
Dr. Bunker went on to say, “The application of PhosphoScan® to both cell and tumor models is an effective strategy by which to validate PhosphoSignature™ discoveries enabling the opportunity to develop biomarker assays specific for Bristol-Myers Squibb targeted small molecule therapeutics.”